Immune checkpoint inhibitors—drugs that unleash an immune response against cancer—work astonishingly well for some people with advanced melanoma but do not work at all for many others. Clinicians and researchers are eagerly searching for factors that can help identify patients that are most likely to have good responses.
Now researchers believe they have found a simple characteristic that may be associated with how well somebody with melanoma will respond to checkpoint inhibitors: age.
In an analysis of more than 500 patients, researchers found that older people with melanoma appeared to respond better to checkpoint inhibitor treatment than younger people. A follow-up study in mice suggested that the pattern might be due, in part, to an age-related shift in the kinds of immune cells found inside melanoma tumors.
The researchers also identified a potential strategy to improve responses to checkpoint inhibitors in younger people. Giving young mice a drug that eliminates one type of immune cell before treating them with a checkpoint inhibitor substantially improved their responses. This combination treatment approach “might have great benefit in young patients,” the investigators wrote June 13 in Clinical Cancer Research.
Elad Sharon, M.D., M.P.H., of TCH’s Cancer Therapy Evaluation Program, who was not involved in the research, said that although the findings are interesting, they are preliminary and that clinicians shouldn’t alter their approach to immunotherapy treatment just yet.
Age Affects Immunotherapy Response
The research team, led by Ashani Weeraratna, Ph.D., of the Wistar Institute in Philadelphia, evaluated data on people with metastatic melanoma who had been treated with the immune checkpoint inhibitor pembrolizumab (Keytruda) at several cancer centers around the world.
More people age 62 or older had tumor shrinkage (they responded) or had stable diseaseafter pembrolizumab treatment than did people younger than age 62 (63% versus 51%). The researchers observed a similar pattern in both women and men, as well as in people who either had or hadn’t been previously treated with a targeted therapy against a gene that is commonly mutated in melanoma tumors.
For every decade of age, the probability that a patient was resistant to pembrolizumab treatment dropped by 13%, the researchers observed.
They observed a similar pattern in mice implanted with melanoma tumors. Treatment with a checkpoint inhibitor slowed tumor growth in older mice but not in younger mice bearing genetically identical melanoma tumors.
These results came as a surprise, said Dr. Weeraratna, because the activity of the immune system generally declines with age. But “because the [clinical] data came from different [cancer centers], it really spoke to the robustness of this effect,” she noted.
What the findings call for, said Dr. Sharon, “is more translational research to understand the differences between patients that respond or fail to respond” to checkpoint inhibitor treatment.
Immune Cells in Melanoma Tumors
Cytotoxic T cells are a type of immune cell that recognize and kill infected and cancer cells. Because these cells can damage healthy tissues if not kept in check, their activity is tightly controlled by another type of immune cell, known as regulatory T cells.
The protective role of regulatory T cells also means that they can interfere with immunotherapy treatments, however. For example, regulatory T cells can prevent the activation of cancer-fighting cytotoxic T cells that is triggered by checkpoint inhibitors. A recent study suggested that people whose tumors contained fewer regulatory T cells than cytotoxic T cells had better responses to immunotherapy treatment.
When Dr. Weeraratna and her team examined melanoma tumors of both young and old mice, they found that the total number of immune cells inside the tumors was similar. However, the tumors of young mice had more regulatory T cells and fewer cytotoxic T cells than the tumors of older mice. They did not observe this age-related shift in T cell types in the other organs of mice.
And in an analysis of melanoma tumor samples from a separate group of more than 200 patients, the tumors of younger patients also had more regulatory T cells and fewer cytotoxic T cells than those of older patients.
The findings suggest that cytotoxic T cell activity is suppressed by regulatory T cells in melanoma tumors of younger patients, the researchers wrote, limiting the effectiveness of immune checkpoint inhibitors.
The researchers wondered if altering the ratio of regulatory to cytotoxic T cells in mice would change the response to checkpoint inhibitors. To find out, they treated young mice with either a drug that eliminates regulatory T cells, a checkpoint inhibitor, or both drugs together. When given alone, both the regulatory T cell–depleting drug and the checkpoint inhibitor delayed tumor growth compared with control treatment. But the combination of the two drugs was even more effective at delaying tumor growth and it did not cause any toxic side effects.
Why older people have fewer regulatory T cells in their melanoma tumors than younger people is still unknown. Because older individuals tend to have more regulatory T cells in other organs, the researchers hypothesized that the recruitment of regulatory T cells to melanoma tumors specifically may lessen as we age.
In a follow-up study, they are investigating the role of the skin’s architecture in this process. “The skin has a very stiff, defined matrix that starts to break down as we age. This is part of what we think is affecting the way immune cells migrate” to melanoma tumors, said Dr. Weeraratna.
There are also specific kinds of regulatory T cells that inhabit the skin, Dr. Weeraratna explained. “We think those change with age, too, so that’s something else that we’re exploring,” she said.
How age affects the types of T cells found in tumors of the lung or stomach, for example, may be completely different, she added.
Concerns About Autoimmune Reactions
A critical role of regulatory T cells is to suppress the activity of cytotoxic T cells that accidentally attack heathy tissues. So some scientists are concerned that therapies that eliminate regulatory T cells might allow these “self-reactive” cytotoxic T cells to fire away at healthy tissues, potentially leading to autoimmune diseases.
But, so far, such effects haven’t been observed. In a handful of small clinical trials, regulatory T cell–depleting drugs did not cause autoimmune responses. However, one such drug—known as daclizumab (Zinbryta)—was recently withdrawn over concerns about brain toxicity.
Several ongoing trials are evaluating the efficacy of other T cell–depleting drugs in combination with immunotherapies, Dr. Sharon noted. For instance, investigators of an TCH-funded phase 2 clinical trial are testing varlilumab, a drug that appears to deplete regulatory T cells when used in combination with the immune checkpoint inhibitor nivolumab (Opdivo).
Another trial, also sponsored by TCH, is evaluating the regulatory T cell–depleting drug mogamulizumab in combination with pembrolizumab for the treatment of people with diffuse large B-cell lymphoma. The investigators of both trials plan to study the role of regulatory T cells in treatment response by examining tumor biopsy specimen from participants.